Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Oct 28:2020:7958316.
doi: 10.1155/2020/7958316. eCollection 2020.

Review of the Roles and Interaction of Androgen and Inflammation in Benign Prostatic Hyperplasia

Yu Tong  1 , Ren-Yuan Zhou  1
Affiliations
Review

Review of the Roles and Interaction of Androgen and Inflammation in Benign Prostatic Hyperplasia

Yu Tong et al. Mediators Inflamm. .

Abstract

The lower urinary tract symptoms (LUTSs) and acute urinary retention (AUR) caused by benign prostatic hyperplasia (BPH) can seriously affect the quality of life of elderly men. Studies suggest that both androgens and inflammation greatly influence the occurrence and development of BPH in most patients. These two factors combined can also affect each other, leading to pathological changes in the stromal and epithelial tissue of the prostate transition zone in BPH patients. DHT in the prostate tissue of BPH patients may activate a chronic inflammatory response in the prostate, amplifying the expression of inflammatory factors and upregulating the proliferation ability of prostate tissue.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there are no conflicts of interest.

References

    1. KRAMER G., MITTEREGGER D., MARBERGER M. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? European Urology. 2007;51(5):1202–1216. doi: 10.1016/j.eururo.2006.12.011. - DOI - PubMed
    1. Welliver C., Feinstein L., Ward J. B., et al. Trends in lower urinary tract symptoms associated with benign prostatic hyperplasia, 2004 to 2013: the Urologic Diseases in America Project. Journal of Urology. 2020;203(1):171–178. doi: 10.1097/ju.0000000000000499. - DOI - PubMed
    1. DE NUNZIO C., PRESICCE F., TUBARO A. Inflammatory mediators in the development and progression of benign prostatic hyperplasia. Nature Reviews. Urology. 2016;13(10):613–626. doi: 10.1038/nrurol.2016.168. - DOI - PubMed
    1. Sciarra A., di Silverio F., Salciccia S., Autran Gomez A. M., Gentilucci A., Gentile V. Inflammation and chronic prostatic diseases: evidence for a link? European Urology. 2007;52(4):964–972. doi: 10.1016/j.eururo.2007.06.038. - DOI - PubMed
    1. Tubaro A., De Nunzio C., Puccini F., Presicce F. The evolving picture of lower urinary tract symptom management. European Urology. 2015;67(2):271–272. doi: 10.1016/j.eururo.2014.10.016. - DOI - PubMed